Why Low-Volume Studies Need a Different Approach

Low-volume studies demand subject-level oversight, where patient context and emerging risks matter more than population-wide trends.

Rethinking Safety Oversight in Small Trials

In small trials, the biggest safety signal may come from a single patient, if your oversight process is designed to see it.

RBQM is moving from concept to capability

RBQM adoption is widespread, but true risk-based monitoring maturity is still rare. Here’s what ACRO’s latest report reveals.

5 Reasons Manual Subject Safety Review Breaks Down in Small Trials

Small trials may have fewer subjects, but manual safety review can still miss critical risks hidden in fragmented data and subtle safety signals.

Generic GCP training is Costing You More Than You Think

Stop wasting time on generic GCP training and equip your team with role-specific learning that improves retention and inspection readiness.

5 Questions to Ask Before Your Next GCP Inspection

Prepare for your next GCP inspection by asking five critical questions that reveal whether your team can apply Good Clinical Practice in real-world scenarios.

Training Shapes Good Clinical Practice Outcomes

Completion proves attendance. Competence proves your GCP quality system actually works under ICH E6(R3).

Completion Isn’t Competence

Completion proves attendance. Competence proves your GCP quality system actually works under ICH E6(R3).

Rethinking Early‑Phase Oversight

Early-phase oversight fails when data is fragmented, and true clinical confidence only comes from seeing signals in full context.

The True Cost of Excel in Subject Review

Excel may feel familiar, but its hidden gaps undermine subject review and create risk long before teams can see it.